{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:13:23Z","timestamp":1790194403680,"version":"4.1.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,5,1]]},"abstract":"<jats:p>The mechanisms underlying aneuploidy in multiple myeloma (MM) are unclear. Centrosome amplification has been implicated as the cause of chromosomal instability in a variety of tumors and is a potential mechanism causing aneuploidy in MM. Using immunofluorescent (IF) staining, centrosome amplification was detected in 67% of monoclonal gammopathies, including monoclonal gammopathy of undetermined significance (MGUS). We also investigated the gene expression of centrosome proteins. Overall, gene expression data correlated well with IF-detected centrosome amplification, allowing us to derive a gene expression-based centrosome index (CI) as a surrogate for centrosome amplification. Clinically, MM patients with high CI (&gt; 4) are associated with poor prognostic genetic and clinical subtypes (chromosome 13 deletion, t(4; 14), t(14;16), and PCLI &gt; 1%, P &lt; .05) and are shown here to have short survival (11.1 months versus 39.1 months, P &lt; .001). On multivariate regression, a high CI is an independent prognostic factor. Given that centrosome amplification is already observed in MGUS and probably integral to early chromosomal instability and myeloma genesis, and patients with more extensive centrosome amplification have shorter survival, the mechanisms leading to centrosome amplification should be investigated because these may offer new avenues for therapeutic intervention.<\/jats:p>","DOI":"10.1182\/blood-2005-09-3810","type":"journal-article","created":{"date-parts":[[2005,12,23]],"date-time":"2005-12-23T02:03:57Z","timestamp":1135303437000},"page":"3669-3675","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":80,"title":["Clinical implication of centrosome amplification in plasma cell neoplasm"],"prefix":"10.1182","volume":"107","author":[{"given":"Wee J.","family":"Chng","sequence":"first","affiliation":[{"name":"From the Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ; the Division of Hematology, Mayo Clinic Rochester and Mayo Clinic Comprehensive Cancer Center, Rochester, MN; the Department of Hematology-Oncology, National University Hospital, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg J.","family":"Ahmann","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ; the Division of Hematology, Mayo Clinic Rochester and Mayo Clinic Comprehensive Cancer Center, Rochester, MN; the Department of Hematology-Oncology, National University Hospital, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Henderson","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ; the Division of Hematology, Mayo Clinic Rochester and Mayo Clinic Comprehensive Cancer Center, Rochester, MN; the Department of Hematology-Oncology, National University Hospital, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Santana-Davila","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ; the Division of Hematology, Mayo Clinic Rochester and Mayo Clinic Comprehensive Cancer Center, Rochester, MN; the Department of Hematology-Oncology, National University Hospital, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip R.","family":"Greipp","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ; the Division of Hematology, Mayo Clinic Rochester and Mayo Clinic Comprehensive Cancer Center, Rochester, MN; the Department of Hematology-Oncology, National University Hospital, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ; the Division of Hematology, Mayo Clinic Rochester and Mayo Clinic Comprehensive Cancer Center, Rochester, MN; the Department of Hematology-Oncology, National University Hospital, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ; the Division of Hematology, Mayo Clinic Rochester and Mayo Clinic Comprehensive Cancer Center, Rochester, MN; the Department of Hematology-Oncology, National University Hospital, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ; the Division of Hematology, Mayo Clinic Rochester and Mayo Clinic Comprehensive Cancer Center, Rochester, MN; the Department of Hematology-Oncology, National University Hospital, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ; the Division of Hematology, Mayo Clinic Rochester and Mayo Clinic Comprehensive Cancer Center, Rochester, MN; the Department of Hematology-Oncology, National University Hospital, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ; the Division of Hematology, Mayo Clinic Rochester and Mayo Clinic Comprehensive Cancer Center, Rochester, MN; the Department of Hematology-Oncology, National University Hospital, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Lust","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ; the Division of Hematology, Mayo Clinic Rochester and Mayo Clinic Comprehensive Cancer Center, Rochester, MN; the Department of Hematology-Oncology, National University Hospital, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ; the Division of Hematology, Mayo Clinic Rochester and Mayo Clinic Comprehensive Cancer Center, Rochester, MN; the Department of Hematology-Oncology, National University Hospital, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Zeldenrust","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ; the Division of Hematology, Mayo Clinic Rochester and Mayo Clinic Comprehensive Cancer Center, Rochester, MN; the Department of Hematology-Oncology, National University Hospital, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne R.","family":"Hayman","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ; the Division of Hematology, Mayo Clinic Rochester and Mayo Clinic Comprehensive Cancer Center, Rochester, MN; the Department of Hematology-Oncology, National University Hospital, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ; the Division of Hematology, Mayo Clinic Rochester and Mayo Clinic Comprehensive Cancer Center, Rochester, MN; the Department of Hematology-Oncology, National University Hospital, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111823170293700_REF1","doi-asserted-by":"crossref","unstructured":"Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396: 643-649.","DOI":"10.1038\/25292"},{"key":"2019111823170293700_REF2","unstructured":"Pihan GA, Purohit A, Wallace J, et al. Centrosome defects and genetic instability in malignant tumors. Cancer Res. 1998;58: 3974-3985."},{"key":"2019111823170293700_REF3","doi-asserted-by":"crossref","unstructured":"Balmain A, Gray J, Ponder B. The genetics and genomics of cancer. Nat Genet. 2003;33(suppl): 238-244.","DOI":"10.1038\/ng1107"},{"key":"2019111823170293700_REF4","doi-asserted-by":"crossref","unstructured":"Pihan G, Doxsey SJ. Mutations and aneuploidy: co-conspirators in cancer? Cancer Cell. 2003;4: 89-94.","DOI":"10.1016\/S1535-6108(03)00195-8"},{"key":"2019111823170293700_REF5","doi-asserted-by":"crossref","unstructured":"Cahill DP, Lengauer C, Yu J, et al. Mutations of mitotic checkpoint genes in human cancers. Nature. 1998;392: 300-303.","DOI":"10.1038\/32688"},{"key":"2019111823170293700_REF6","doi-asserted-by":"crossref","unstructured":"Bornens M. Centrosome composition and microtubule anchoring mechanisms. Curr Opin Cell Biol. 2002;14: 25-34.","DOI":"10.1016\/S0955-0674(01)00290-3"},{"key":"2019111823170293700_REF7","doi-asserted-by":"crossref","unstructured":"D'Assoro AB, Lingle WL, Salisbury JL. Centrosome amplification and the development of cancer. Oncogene. 2002;21: 6146-6153.","DOI":"10.1038\/sj.onc.1205772"},{"key":"2019111823170293700_","doi-asserted-by":"crossref","unstructured":"Kramer A, Neben K, Ho AD. Centrosome replication, genomic instability and cancer. Leukemia. 2002;16: 767-775.","DOI":"10.1038\/sj.leu.2402454"},{"key":"2019111823170293700_REF9","doi-asserted-by":"crossref","unstructured":"Nigg EA. Centrosome aberrations: cause or consequence of cancer progression? Nat Rev Cancer. 2002;2: 815-825.","DOI":"10.1038\/nrc924"},{"key":"2019111823170293700_REF10","doi-asserted-by":"crossref","unstructured":"Sluder G, Nordberg JJ. The good, the bad and the ugly: the practical consequences of centrosome amplification. Curr Opin Cell Biol. 2004;16: 49-54.","DOI":"10.1016\/j.ceb.2003.11.006"},{"key":"2019111823170293700_REF11","doi-asserted-by":"crossref","unstructured":"Gustafson LM, Gleich LL, Fukasawa K, et al. Centrosome hyperamplification in head and neck squamous cell carcinoma: a potential phenotypic marker of tumor aggressiveness. Laryngoscope. 2000;110: 1798-1801.","DOI":"10.1097\/00005537-200011000-00004"},{"key":"2019111823170293700_REF12","doi-asserted-by":"crossref","unstructured":"Kuo KK, Sato N, Mizumoto K, et al. Centrosome abnormalities in human carcinomas of the gall-bladder and intrahepatic and extrahepatic bile ducts. Hepatology. 2000;31: 59-64.","DOI":"10.1002\/hep.510310112"},{"key":"2019111823170293700_REF13","doi-asserted-by":"crossref","unstructured":"Lingle WL, Lutz WH, Ingle JN, Maihle NJ, Salisbury JL. Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell polarity. Proc Natl Acad Sci U S A. 1998; 95: 2950-2955.","DOI":"10.1073\/pnas.95.6.2950"},{"key":"2019111823170293700_","doi-asserted-by":"crossref","unstructured":"Lingle WL, Salisbury JL. Altered centrosome structure is associated with abnormal mitoses in human breast tumors. Am J Pathol. 1999;155: 1941-1951.","DOI":"10.1016\/S0002-9440(10)65513-7"},{"key":"2019111823170293700_REF15","unstructured":"Pihan GA, Purohit A, Wallace J, Malhotra R, Liotta L, Doxsey SJ. Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression. Cancer Res. 2001;61: 2212-2219."},{"key":"2019111823170293700_REF16","unstructured":"Sato N, Mizumoto K, Nakamura M, et al. Centrosome abnormalities in pancreatic ductal carcinoma. Clin Cancer Res. 1999;5: 963-970."},{"key":"2019111823170293700_REF17","doi-asserted-by":"crossref","unstructured":"Giehl M, Fabarius A, Frank O, et al. Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability. Leukemia. 2005;19: 1192-1197.","DOI":"10.1038\/sj.leu.2403779"},{"key":"2019111823170293700_REF18","doi-asserted-by":"crossref","unstructured":"Neben K, Tews B, Wrobel G, et al. Gene expression patterns in acute myeloid leukemia correlate with centrosome aberrations and numerical chromosome changes. Oncogene. 2004;23: 2379-2384.","DOI":"10.1038\/sj.onc.1207401"},{"key":"2019111823170293700_REF19","doi-asserted-by":"crossref","unstructured":"Duensing S, Lee BH, Dal Cin P, Munger K. Excessive centrosome abnormalities without ongoing numerical chromosome instability in a Burkitt's lymphoma. Mol Cancer. 2003;2: 30.","DOI":"10.1186\/1476-4598-2-30"},{"key":"2019111823170293700_","doi-asserted-by":"crossref","unstructured":"Kramer A, Schweizer S, Neben K, et al. Centrosome aberrations as a possible mechanism for chromosomal instability in non-Hodgkin's lymphoma. Leukemia. 2003;17: 2207-2213.","DOI":"10.1038\/sj.leu.2403142"},{"key":"2019111823170293700_REF21","doi-asserted-by":"crossref","unstructured":"Ventura RA, Martin-Subero JI, Knippschild U, et al. Centrosome abnormalities in ALK-positive anaplastic large-cell lymphoma. Leukemia. 2004; 18: 1910-1911.","DOI":"10.1038\/sj.leu.2403470"},{"key":"2019111823170293700_REF22","doi-asserted-by":"crossref","unstructured":"Lingle WL, Barrett SL, Negron VC, et al. Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci U S A. 2002;99: 1978-1983.","DOI":"10.1073\/pnas.032479999"},{"key":"2019111823170293700_REF23","unstructured":"Pihan GA, Wallace J, Zhou Y, Doxsey SJ. Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas. Cancer Res. 2003;63: 1398-1404."},{"key":"2019111823170293700_REF24","doi-asserted-by":"crossref","unstructured":"Zandecki M, Lai JL, Facon T. Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol. 1996;94: 217-227.","DOI":"10.1046\/j.1365-2141.1996.d01-2939.x"},{"key":"2019111823170293700_REF25","doi-asserted-by":"crossref","unstructured":"The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121: 749-757.","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"key":"2019111823170293700_REF26","doi-asserted-by":"crossref","unstructured":"Salisbury JL. Centrin, centrosomes, and mitotic spindle poles. Curr Opin Cell Biol. 1995;7: 39-45.","DOI":"10.1016\/0955-0674(95)80043-3"},{"key":"2019111823170293700_REF27","doi-asserted-by":"crossref","unstructured":"Abraham RS, Ballman KV, Dispenzieri A, et al. Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. Blood. 2005;105: 794-803.","DOI":"10.1182\/blood-2004-04-1424"},{"key":"2019111823170293700_REF28","doi-asserted-by":"crossref","unstructured":"Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106: 296-303.","DOI":"10.1182\/blood-2005-01-0034"},{"key":"2019111823170293700_REF29","doi-asserted-by":"crossref","unstructured":"Ahmann GJ, Jalal SM, Juneau AL, et al. A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet. 1998;101: 7-11.","DOI":"10.1016\/S0165-4608(97)00058-7"},{"key":"2019111823170293700_REF30","doi-asserted-by":"crossref","unstructured":"Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101: 4569-4575.","DOI":"10.1182\/blood-2002-10-3017"},{"key":"2019111823170293700_REF31","doi-asserted-by":"crossref","unstructured":"Chng WJ, Van Wier SA, Ahmann GJ, et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood. 2005;106: 2156-2161.","DOI":"10.1182\/blood-2005-02-0761"},{"key":"2019111823170293700_REF32","doi-asserted-by":"crossref","unstructured":"Greipp PR, Trendle MC, Leong T, et al. Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma? Leuk Lymphoma. 1999;35: 83-89.","DOI":"10.3109\/10428199909145707"},{"key":"2019111823170293700_REF33","doi-asserted-by":"crossref","unstructured":"Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood. 1993;81: 3382-3387.","DOI":"10.1182\/blood.V81.12.3382.3382"},{"key":"2019111823170293700_REF34","doi-asserted-by":"crossref","unstructured":"Wang Q, Hirohashi Y, Furuuchi K, et al. The centrosome in normal and transformed cells. DNA Cell Biol. 2004;23: 475-489.","DOI":"10.1089\/1044549041562276"},{"key":"2019111823170293700_REF35","doi-asserted-by":"crossref","unstructured":"Yaccoby S, Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood. 1999;94: 3576-3582.","DOI":"10.1182\/blood.V94.10.3576.422k01_3576_3582"},{"key":"2019111823170293700_REF36","doi-asserted-by":"crossref","unstructured":"Maxwell CA, Keats JJ, Belch AR, Pilarski LM, Reiman T. Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity. Cancer Res. 2005;65: 850-860.","DOI":"10.1158\/0008-5472.850.65.3"},{"key":"2019111823170293700_REF37","doi-asserted-by":"crossref","unstructured":"Smadja NV, Fruchart C, Isnard F, et al. Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia. 1998;12: 960-969.","DOI":"10.1038\/sj.leu.2401041"},{"key":"2019111823170293700_REF38","doi-asserted-by":"crossref","unstructured":"Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64: 1546-1558.","DOI":"10.1158\/0008-5472.CAN-03-2876"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/9\/3669\/469806\/zh800906003669.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/9\/3669\/469806\/zh800906003669.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:25:44Z","timestamp":1683332744000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/9\/3669\/133461\/Clinical-implication-of-centrosome-amplification"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,1]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,5,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-09-3810","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,1]]}}}